PCT Chapter II Demand Strategy: Preliminary Examination, Amendments and IPER Value

TL;DR
A PCT Chapter II demand requests international preliminary examination and allows Article 34 amendments and arguments before the International Preliminary Examining Authority (IPEA). The resulting International Preliminary Report on Patentability (IPER) is non-binding but can influence national phase examination, provide early feedback, and support enforcement or licensing narratives. Many applicants skip Chapter II and go straight to national phase. See our continuation and divisional filing strategy guide by the PatentPaper research team for US national phase claim strategy and our PCT national phase strategies guide by the PatentPaper research team for entry timing and claim set selection.

When Chapter II Adds Value Versus Direct National Phase Entry

Chapter II is most useful when the ISR contains significant novelty or inventive step objections that can be overcome with amendments or arguments that will carry weight in multiple key jurisdictions. It is less useful when the ISR is clean, when the applicant plans major claim revisions per jurisdiction anyway, or when budget and timeline favor immediate national filings.

Example: A European university filed Chapter II after a negative ISR on its CRISPR delivery vector claims. The Article 34 response narrowed to a specific capsid variant supported by new data and persuaded the EPO as IPEA to issue a positive IPER on the amended claims. The positive IPER was then used to accelerate examination in Japan, Korea and Canada with minimal further amendment.

Article 34 Amendments: Scope, Timing and Support Requirements

Amendments under Article 34 must not go beyond the disclosure of the international application as filed. They can be broader or narrower than claims examined in Chapter I. The demand must be filed within 3 months of the ISR transmittal or 22 months from priority, whichever is later. Amendments are submitted with the demand or in response to the written opinion.

Choice of IPEA and Examiner Quality Considerations

Applicants can choose among competent IPEAs (EPO, USPTO, JPO, KIPO, CNIPA, etc.). EPO and JPO are often selected for technically complex cases because of examiner expertise and the persuasive weight of their IPERs in other offices. USPTO as IPEA may be faster and cheaper for US applicants but its IPERs sometimes receive less deference abroad.

IPER Influence on National Phase Examination and Accelerated Programs

A positive IPER can support PPH requests, accelerated examination petitions, or simple fast-track requests in many offices. A negative IPER does not bind national examiners but can frame the issues and force the applicant to address them early. Some offices (e.g., EPO in certain cases) give the IPER significant weight in the first national office action.

Strategic Downsides: Cost, Timeline and Potential Admissions

Chapter II adds official fees and attorney costs. The IPER issues relatively late (around 28-30 months), so it may arrive after some national deadlines have passed. Arguments made in Chapter II can create prosecution history that is later used against the applicant in national courts or oppositions. Some applicants prefer to keep their powder dry for jurisdiction-specific prosecution.

FAQ

Is the IPER binding on national patent offices?

No. The IPER is advisory only. National offices conduct their own examination, though they often consider the IPER and may adopt its reasoning.

Can I amend claims in Chapter II beyond what was in the ISR?

Yes, provided the amendments find support in the application as filed. You can introduce new claims or broaden within the original disclosure.

Which IPEA is best for a software/AI invention?

Many applicants choose the EPO or JPO for complex software cases because of technical depth. The USPTO is also competent and may be more familiar with US-style claim drafting. Choice depends on budget, timeline and target jurisdictions.

Does a positive IPER guarantee faster national phase allowance?

Not guarantee, but it often supports PPH or other accelerated programs and can lead to fewer or narrower office actions in offices that respect the IPEA's work.

Should I file Chapter II if the ISR is already positive?

Often no. A positive ISR already provides most of the benefit for PPH and accelerated programs. Chapter II adds cost with limited incremental value unless you want to lock in amendments or obtain a formal IPER for licensing or enforcement purposes.

What is the latest date to file a Chapter II demand?

Generally 3 months from the date the ISR and written opinion are transmitted to the applicant, or 22 months from the priority date, whichever expires later. Check the specific IPEA rules.

Which PatentPaper resources discuss PCT national phase entry and continuation strategy?

Our PCT national phase strategies guide and continuation and divisional filing strategy guide by the PatentPaper research team cover entry timing, claim set selection, and US continuation practice that interacts with PCT decisions.

Review layer 1: Practical review notes for PCT Chapter II Demand Strategy: Preliminary Examination, Amendments and IPER Value

Review layer 1: For pct chapter ii demand strategy, separate the legal basis, patent-office step, and commercial evidence needed in a dispute. Sources such as wipo.int, epo.org, uspto.gov help confirm fees, deadlines, term, and forum from primary material rather than secondary summaries.

Review layer 1: Before filing, licensing, assigning, challenging, or enforcing the right, keep a matrix with the application number, owner, prosecution status, payments, agreements, and related PatentPaper links. That record makes later decisions easier to defend.

Review layer 1: Check legal status before sending a notice.
Review layer 1: Save official receipts and office correspondence.
Review layer 1: Compare the main claim with the product actually sold.